drugset / Trial / NCT00449280

Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies

NCT00449280

Phase 1 Completed 34 enrolled University of Chicago Bayer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib. This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.

Timeline

Start
2006-11
Primary completion
2009-06
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 3 mg
Subject Sirolimus Small molecule 30 mg
Subject Sorafenib Small molecule 200 mg